Investment & M&A transaction comps
Women's Health Investment & M&A Transaction Comps
Explore investment and M&A transactions tagged women's health. Compare companies, buyers, dates and available valuation multiples, with reported, estimated or rumored figures clearly labelled in each comp.
Coverage includes published FundComb transactions carrying this tag. Each comp preserves its own source notes and valuation basis.
- Reviewed transactions
- 4
- With value data
- 3
- With revenue multiples
- 2
- Transaction years
- 2021–2026
Sortable transaction comps
Women's Health transaction table
Rows with reported value
3 / 4
Acquisition EV, USD
USD 2.7B
Investment EV, USD
-
Median EV / revenue
4.0x
Selected comparison set
Saved in this browser only. Nothing is written to FundComb data.
Choose transactions from the table to build a quick comparison set.
4 shown of 4 matching transactions. Click any transaction row for more detail.
Values are 100% enterprise values. Multiples divide EV by full-company revenue or EBITDA. Reported prices are assumed to be EV; explicit partial-stake prices are grossed up as estimates. Amounts paid are tracked separately, and a financing without a reported valuation shows its amount raised, not an EV.
| Select for comparison | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Zywie Ventures Private Limited (OZiva) Control (49%) | 2026-02-12 | Hindustan Unilever Limited (HUL) | INR 17B Enterprise Value | 186 | 3.5x | - | India | Confirmed 6 sources | ||
| Bonafide Health Control | 2023-11-30 | Pharmavite | USD 425M Consideration | 425 | - | - | - | Confirmed 1 source | ||
| Héra / HRA Pharma Control | 2021-09-08 | Perrigo | USD 2.1B | 2,100 | 4.5x | - | - | Estimated 3 sources | ||
| Uqora Control | 2021-07-08 | Pharmavite | Undisclosed | Undisclosed | - | - | United States | Confirmed 1 source |
Explore related tags
Continue to the full transaction history for each tag.
Explore buyers & investors
Source coverage varies by transaction. Announced deals, minority investments and capital raises retain their own labels; an investment amount is separate from enterprise value. Read the methodology.